Study for ART Adherence Among Latino Men With HIV
This study is testing ways to help Latino men with HIV take their ART (antiretroviral therapy) medications regularly. Researchers are comparing two strategies: one starts with personalized text messages (TXTXT) and adds remote patient navigation if needed. The other starts with TXTXT plus e-Navigation (which includes patient navigation, care coordination, and HIV self-management) and adds EMA-supported e-Navigation (Ecological Momentary Assessment, which uses surveys to check for adherence barriers) if needed. The goal is to see which approach works best to improve ART adherence over 6 and 12 months. You may be able to join if you are a Latino man, 18 or older, living with HIV, and have had difficulty taking your ART medications as prescribed.
- Study design
- This is an interventional study with a planned enrollment of 250 participants. It uses a SMART (sequential, multiple assignment, randomized trial) design to compare different stepped care strategies.
- What's involved
- Participants will receive daily text message reminders for six months. Some participants may also have remote one-on-one sessions or complete short surveys three times per week.
- Compensation
- Not stated in the trial record.
- Follow-up
- ART adherence will be measured at the end of the 6-month intervention and again 6 months after the intervention ends (at 12 months).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Efficacy of mHealth + e-Navigator Stepped Care Intervention for ART Adherence Among Latino Men With HIV
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Michelle M Hospi\utal, Ph.D, LMHC · PRINCIPAL_INVESTIGATOR · Florida International University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- ART adherenceART adherence will be measured at each study visit. For efficacy analysis, ART adherence will be measured at 6-months (end of intervention) and at 12-months (6-months post-intervention).
ART adherence will be measured by self-report at each visit and by electronic pill dispenser throughout the study for both arms. Past 30-day adherence will be measured using a validated single-item Visual Analog Scale (VAS). Additionally, we will measure adherence through a Wisepill dispenser. The dispenser collects time-stamped data each time the dispenser is opened. Self-reported and Wisepill data will be analyzed as a continuous measure (proportion of pills taken) and dichotomized as adherent (≥90% of pills in past 30 days) and non-adherent (\<90%).